Vertically integrated cannabis company C21 Investments Inc. CXXI CXXIF announced on Tuesday its plan to repurchase approximately 5% of its issued and outstanding common shares as part of a share buyback program, with the intention of canceling the repurchased shares to enhance shareholder value.
What Happened
Under the normal course issuer bid (NCIB), C21 may repurchase up to 6,002,390 of its common shares, representing 5% of its total issued and outstanding shares.
The program will run for a year, starting Monday, Dec. 2, 2024, providing the company with the flexibility to make purchases when market conditions are favorable. Purchases will depend on market conditions, and C21 retains the right to suspend or discontinue the program at any time.
The company has appointed Haywood Securities Inc. as its broker to conduct the NCIB transactions on its behalf.
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
Why It Matters
C21 said in a press release it opted for the move as it "believes that the market price of the common shares may not fully reflect the value of its business and prospects," adding that "purchasing its own common shares for cancellation is an appropriate strategy for increasing long-term shareholder value and represents an appropriate use of the company’s financial resources."
According to the company's Nov. 14 earnings report, its second-quarter revenue totaled $7.5 million, representing a 14% increase from the first quarter.
The company highlighted strong sales growth in its South Reno dispensary, with a 53% increase during the second quarter, reaching $416,000 in September. Sales continued to grow in October, rising another 14% to $475,000. These results underscore the company’s ability to fund the share buyback program while continuing to expand its operations.
CEO and president Sonny Newman said quarterly results “have exceeded our expectations and we continue to see robust sales growth into the new quarter."
The company’s shares traded 4.34% higher at 23 cents per share at the time of writing on Wednesday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.